Diagnostic value of positron emission tomography using amyloid-binding radiotracers for cardiac amyloidosis: a systematic review and meta-analysis

Clicks: 1
ID: 325288
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #46 of 47 articles by views in European Heart Journal - Imaging Methods and Practice

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Amyloid-binding positron emission tomography (PET) tracers have emerged as a promising non-invasive tool for the diagnosis of cardiac amyloidosis (CA). This study aimed to assess the diagnostic accuracy of amyloid PET for detecting CA through a meta-analysis of diagnostic test accuracy. Methods PubMed, Cochrane Library, Embase, and Web of Science were searched through March 16, 2026 for studies reporting the diagnostic performance of amyloid PET for CA. The primary analysis was a bivariate random-effects (Reitsma) model yielding summary sensitivity, specificity, the summary ROC curve with corresponding area under the curve (AUC), and positive and negative likelihood ratios. Subgroup analyses were performed by radiotracer and by amyloid subtype. Risk of bias was assessed using QUADAS-2 and publication bias by Deeks’ funnel-plot asymmetry test. Results Twenty studies comprising 577 patients (407 with CA, 170 controls) met inclusion criteria, covering five radiotracers (11C-PiB, 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol, and 124I-evuzamitide). In the primary bivariate model (k=17), amyloid PET demonstrated a summary sensitivity of 0.91 (95% CI 0.83–0.96), specificity of 0.90 (95% CI 0.79–0.96), and AUC of 0.96, with low between-study heterogeneity (sensitivity I2=13.4%; specificity I2=0%). Sensitivity was high and consistent across 11C-PiB, 18F-florbetaben, 18F-florbetapir, and 124I-evuzamitide (0.96–1.00), with the exception of 18F-flutemetamol, which showed lower and heterogeneous sensitivity (0.70). Conclusion Amyloid PET demonstrates high sensitivity and specificity for CA detection, even though the evidence base remains limited in terms of the number and scope of available studies. Prospective multicentre studies in consecutive patients with suspected CA are required to establish its clinical role and standardize acquisition protocols.
Reference Key
openalex_W7203719153 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Amely Walser, Konstantinos Bitos, Andreas A. Giannopoulos, Aju P. Pazhenkottil, Valérie Treyer, Martin W. Huellner, Ronny R. Buechel, Philipp A. Kaufmann, Dominik C. Benz
Journal European Heart Journal - Imaging Methods and Practice
Year 2026
DOI
10.1093/ehjimp/qyag141
URL
https://doi.org/10.1093/ehjimp/qyag141
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.